• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $INMB

    INmune Bio Inc.

    Subscribe to $INMB
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: inmunebio.com

    Peers

    $BXRX
    $GOSS
    $PRVB
    $SESN
    $IBRX
    $TIL
    $PALI
    $GRPH

    Recent Analyst Ratings for INmune Bio Inc.

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Buy
    Rodman & Renshaw
    10/21/2024$20.00Buy
    Alliance Global Partners
    9/27/2024$18.00Outperform
    Raymond James
    8/22/2024$22.00Sector Outperform
    Scotiabank
    6/1/2023$16.00Outperform
    Robert W. Baird
    5/24/2022$14.00 → $7.00Buy → Neutral
    B. Riley Securities
    1/24/2022$32.00 → $20.00Buy
    B. Riley Securities
    7/7/2021$32.00 → $42.00Buy
    Maxim Group
    See more ratings

    INmune Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

      BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY. 2025 RBC Capital Markets Global Healthcare Conference May 20-21, 2025Format: Fireside Chat and 1-on-1 virtual meetingsPresentation Time: 11:00am EDT About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ:INMB), clinical-stage biotechnology company focused on developing treatments that target the innate

      5/14/25 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

      Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: May 8th, 2025 Time: 4:30 PM Eastern Tim

      5/5/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

      Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property milestone with respect to its next-generation mesenchymal stromal cell (MSC) product, CORDStrom™. The United States Patent and Trademark Office (USPTO), acting as the International Search Authority, has issued a favorable written opinion on all claims in INmune Bio's international patent application PCT/US25/17028, titled "THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS." The w

      4/16/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

      Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK. INmune Bio's therapies harness the innate immune system, the body's first line of defense, to treat diseases incl

      4/14/25 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

      MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting a poster at the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders taking place in Vienna, Austria April 1-5 2025.  AD/PD is the largest Alzheimer's conference in Europe. The poster details the demographics and biomarker status of patients at the time of enrollment in the MINDFul Phase II

      4/1/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

      BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n

      3/27/25 4:05:56 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

      Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li

      3/24/25 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

      Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the "CaRe PC" trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort. The Scientific Review Committee (SRC) charter is to re

      2/12/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

      The Company reports results of a double-blinded, randomized, placebo-controlled study, known as "MissionEB," investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications for marketing authorization. CORDStrom, developed by INmune Bio is a patent pending, off the shelf, advanced mesenchymal stromal cell (MSC) platform developed to treat complex inflammatory diseases that has significant clinical development advantages over current MSC products.FDA grants CORDStrom a Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for treatment of epidermolysis bullosa (EB).Parallel effor

      2/10/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

      First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton, Florida, Jan. 28, 2025 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, has an ongoing Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the participation of a patient at the West Los Angeles VA Medical Center in the trial. The participant received the investigational intervention, as an out-p

      1/28/25 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/30/24 4:01:02 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/16/24 8:48:44 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/16/24 8:47:21 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      6/26/24 8:00:03 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moss David J bought $149,993 worth of shares (18,028 units at $8.32), increasing direct ownership by 1% to 1,268,179 units (SEC Form 4) (Amendment)

      4/A - Inmune Bio, Inc. (0001711754) (Issuer)

      4/24/24 2:10:19 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tesi Raymond Joseph bought $149,993 worth of shares (18,028 units at $8.32), increasing direct ownership by 1% to 1,538,726 units (SEC Form 4) (Amendment)

      4/A - Inmune Bio, Inc. (0001711754) (Issuer)

      4/24/24 2:08:45 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lowdell Mark William bought $119,999 worth of shares (14,423 units at $8.32), increasing direct ownership by 0.96% to 1,510,806 units (SEC Form 4) (Amendment)

      4/A - Inmune Bio, Inc. (0001711754) (Issuer)

      4/24/24 2:08:04 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Juda Scott bought $246,297 worth of shares (29,603 units at $8.32), increasing direct ownership by 80% to 66,603 units (SEC Form 4) (Amendment)

      4/A - Inmune Bio, Inc. (0001711754) (Issuer)

      4/24/24 2:07:17 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Juda Scott bought $48,650 worth of shares (7,000 units at $6.95) (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      11/13/23 11:31:53 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. SEC Filings

    See more
    • INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      5/14/25 4:00:22 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by INmune Bio Inc.

      DEFR14A - Inmune Bio, Inc. (0001711754) (Filer)

      5/9/25 4:05:05 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      5/8/25 4:18:20 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by INmune Bio Inc.

      10-Q - Inmune Bio, Inc. (0001711754) (Filer)

      5/8/25 4:15:57 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      5/7/25 5:20:59 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      5/5/25 4:46:52 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by INmune Bio Inc.

      DEFA14A - Inmune Bio, Inc. (0001711754) (Filer)

      4/25/25 4:05:02 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by INmune Bio Inc.

      DEF 14A - Inmune Bio, Inc. (0001711754) (Filer)

      4/21/25 4:06:16 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      4/16/25 4:01:15 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      4/14/25 4:30:31 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by INmune Bio Inc.

      SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

      10/25/24 10:15:45 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by INmune Bio Inc.

      SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)

      10/2/24 4:50:56 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by INmune Bio Inc.

      SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

      2/15/23 5:06:34 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by INmune Bio Inc. (Amendment)

      SC 13D/A - Inmune Bio, Inc. (0001711754) (Subject)

      4/21/22 4:30:21 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by INmune Bio Inc. (Amendment)

      SC 13D/A - Inmune Bio, Inc. (0001711754) (Subject)

      4/21/22 4:30:21 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by INmune Bio Inc. (Amendment)

      SC 13D/A - Inmune Bio, Inc. (0001711754) (Subject)

      4/21/22 4:30:21 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by INmune Bio Inc. (Amendment)

      SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)

      2/14/22 6:09:18 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by INmune Bio Inc. (Amendment)

      SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)

      2/10/22 12:40:41 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by INmune Bio Inc.

      SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

      7/19/21 9:25:13 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • INmune Bio Inc. to Join Russell 3000® Index

      Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion

      5/30/24 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

      DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o

      11/15/21 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on INmune Bio with a new price target

      Rodman & Renshaw initiated coverage of INmune Bio with a rating of Buy and set a new price target of $23.00

      1/28/25 7:14:13 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on INmune Bio with a new price target

      Alliance Global Partners initiated coverage of INmune Bio with a rating of Buy and set a new price target of $20.00

      10/21/24 7:55:01 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on INmune Bio with a new price target

      Raymond James initiated coverage of INmune Bio with a rating of Outperform and set a new price target of $18.00

      9/27/24 7:36:48 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on INmune Bio with a new price target

      Scotiabank initiated coverage of INmune Bio with a rating of Sector Outperform and set a new price target of $22.00

      8/22/24 7:30:58 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on INmune Bio with a new price target

      Robert W. Baird initiated coverage of INmune Bio with a rating of Outperform and set a new price target of $16.00

      6/1/23 7:25:12 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded INmune Bio from Buy to Neutral and set a new price target of $7.00 from $14.00 previously

      5/24/22 8:32:30 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities reiterated coverage on INmune Bio with a new price target

      B. Riley Securities reiterated coverage of INmune Bio with a rating of Buy and set a new price target of $20.00 from $32.00 previously

      1/24/22 8:56:27 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group reiterated coverage on INmune Bio with a new price target

      Maxim Group reiterated coverage of INmune Bio with a rating of Buy and set a new price target of $42.00 from $32.00 previously

      7/7/21 9:18:25 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley FBR initiated coverage on INmune Bio with a new price target

      B. Riley FBR initiated coverage of INmune Bio with a rating of Buy and set a new price target of $29.00

      4/21/21 6:35:17 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group resumed coverage on INmune Bio with a new price target

      Maxim Group resumed coverage of INmune Bio with a rating of Buy and set a new price target of $13.00

      2/9/21 4:10:32 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ganjei James Kelly

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:24 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Juda Scott

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:27 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Allen Marcia

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:27 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Lowdell Mark William

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:29 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Schroeder Timothy J

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:26 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Moss David J

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:30 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Tesi Raymond Joseph

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:25 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/30/24 4:01:02 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/16/24 8:48:44 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/16/24 8:47:21 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

      Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

      6/26/24 2:54:12 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    INmune Bio Inc. Financials

    Live finance-specific insights

    See more
    • INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

      Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: May 8th, 2025 Time: 4:30 PM Eastern Tim

      5/5/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

      BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n

      3/27/25 4:05:56 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

      Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li

      3/24/25 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

      BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.

      10/31/24 4:05:51 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

      Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"),  a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update.  Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the IN

      10/24/24 9:30:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

      Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2024 and provides a business update. Q2 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The Phase 2 randomized, blinded clinical trial for patients with Early Alzheimer's Disease is on schedule to reach its final enrollment before the end of Q3 followed by top-line data approximately six months fr

      8/1/24 4:05:39 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

      Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 PM EDT to discuss results for its first quarter ended June 30, 2024 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Fourth Quarter Conference Call when r

      7/25/24 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

      BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update. Q1 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The AD02 randomized, blinded program for patients with Early Alzheimer's Disease remains on schedule to reach its final enrollment target by mid-2024, with top-line data expected to be presented approximately six months after the last patient is enrolled. The trial is currently

      5/9/24 4:05:36 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

      Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 PM EDT to discuss results for its first quarter ended March 31, 2024 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Fourth Quarter Conference Call whe

      5/7/24 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

      BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2023 and provides a business update. Q4 2023 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro™): The AD02 randomized, blinded program for patients with Early Alzheimer's Disease remains on schedule to reach its final enrollment target by mid-2024, with top-line data expected to be presented approximately six months after the last patient is enrolled. The trial is curren

      3/28/24 4:01:53 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care